Weight Loss Drugs Won’t Eat Into Food Industry Profits, Nestlé CEO Says

  • 📰 ForbesTech
  • ⏱ Reading Time:
  • 12 sec. here
  • 11 min. at publisher
  • 📊 Quality Score:
  • News: 39%
  • Publisher: 59%

Mark Schneider News

Nestle,Glp-1,Ozempic

Robert Hart is a senior reporter for Forbes covering science, technology and health with a frequent focus on artificial intelligence, space, weight loss drugs and emerging technologies. He joined Forbes in 2020 and is based in London. Rob has covered everything from the billionaire space race, the health impacts of overturning Roe v.

Nestlé is tapping into the lucrative weight loss drug market by catering to customers’ “shifting” nutritional needs, CEO Mark SchneiderCNBC on Thursday, an optimistic pivot from one of the industry’s biggest players in the face of dire early predictions suggesting wildly popular drugs like Ozempic, Mounjaro and Wegovy would take a bite out of the food industry.

Schneider said the different needs of people using weight loss drugs open up a big market opportunity for companies like Nestlé, which he said has big plans to respond to what has rapidly become a “major consumer trend.”

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 318. in BUSİNESS

Business Business Latest News, Business Business Headlines